130 related articles for article (PubMed ID: 24166514)
1. Complicated puzzle in cetuximab-based chemotherapy: skin toxicity and resection rate in patients with initially unresectable colorectal liver metastases.
Sunakawa Y; Takahashi T; Ichikawa W; Shimada K; Sasaki Y
J Clin Oncol; 2013 Dec; 31(35):4473. PubMed ID: 24166514
[No Abstract] [Full Text] [Related]
2. Surgery: Cetuximab--an option for unresectable CRC liver metastases.
Laurent-Puig P; Benhaim L
Nat Rev Clin Oncol; 2013 Jul; 10(7):374-5. PubMed ID: 23736647
[No Abstract] [Full Text] [Related]
3. Treatment of metastatic colon cancer: "the times they are A-changing".
Kemeny NE
J Clin Oncol; 2013 Jun; 31(16):1913-6. PubMed ID: 23630214
[No Abstract] [Full Text] [Related]
4. When inoperable becomes operable?
Mroczkowski P; Seidensticker M
J Clin Oncol; 2013 Dec; 31(35):4474. PubMed ID: 24166527
[No Abstract] [Full Text] [Related]
5. Liver resection rate following downsizing chemotherapy with cetuximab in metastatic colorectal cancer: UK retrospective observational study.
Malik H; Khan AZ; Berry DP; Cameron IC; Pope I; Sherlock D; Helmy S; Byrne B; Thompson M; Pulfer A; Davidson B
Eur J Surg Oncol; 2015 Apr; 41(4):499-505. PubMed ID: 25703078
[TBL] [Abstract][Full Text] [Related]
6. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis.
Ji JH; Park SH; Lee J; Kim TW; Hong YS; Kim KP; Kim SY; Baek JY; Kang HJ; Shin SJ; Shim BY; Park YS
Cancer Chemother Pharmacol; 2013 Jul; 72(1):223-30. PubMed ID: 23689915
[TBL] [Abstract][Full Text] [Related]
7. Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.
Stremitzer S; Stift J; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
Eur J Surg Oncol; 2015 Jul; 41(7):868-74. PubMed ID: 25865557
[TBL] [Abstract][Full Text] [Related]
8. Complete resection of unresectable liver metastases from colorectal cancer without deterioration of liver function after cetuximab and irinotecan: two case reports.
Karasaki T; Sano K; Takamoto T; Kinoshita H; Tateishi R; Takemura T; Makuuchi M
Hepatogastroenterology; 2010; 57(104):1526-8. PubMed ID: 21443115
[TBL] [Abstract][Full Text] [Related]
9. Impact of early tumor shrinkage on clinical outcome in wild-type-KRAS colorectal liver metastases treated with cetuximab.
Ye LC; Wei Y; Zhu DX; Chen T; Xu J
J Gastroenterol Hepatol; 2015 Apr; 30(4):674-9. PubMed ID: 25387601
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy and immunotherapy in metastatic colorectal cancer.
Loupakis F; Di Maio M; Falcone A
N Engl J Med; 2009 May; 360(20):2135; author reply 2135-6. PubMed ID: 19445032
[No Abstract] [Full Text] [Related]
11. Adjuvant therapy after hepatectomy for colorectal metastases.
Fong Y
Lancet Oncol; 2014 May; 15(6):544-5. PubMed ID: 24807857
[No Abstract] [Full Text] [Related]
12. Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens.
Huang MY; Chen MJ; Tsai HL; Kuo CH; Ma CJ; Hou MF; Chuang SC; Lin SR; Wang JY
Genet Mol Res; 2011 Oct; 10(4):3002-12. PubMed ID: 21968808
[TBL] [Abstract][Full Text] [Related]
13. Cetuximab or Bevacizumab With First-Line Chemotherapy in Advanced KRAS Wild-Type Colorectal Cancer: No Difference, but Not the Same.
Lieu CH; Messersmith WA
JAMA; 2017 Jun; 317(23):2376-2378. PubMed ID: 28632850
[No Abstract] [Full Text] [Related]
14. Hurdles and complexities of codon 13 KRAS mutations.
Morelli MP; Kopetz S
J Clin Oncol; 2012 Oct; 30(29):3565-7. PubMed ID: 22927534
[No Abstract] [Full Text] [Related]
15. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.
Colucci G; Giuliani F; Garufi C; Mattioli R; Manzione L; Russo A; Lopez M; Parrella P; Tommasi S; Copetti M; Daniele B; Pisconti S; Tuveri G; Silvestris N; Maiello E
Oncology; 2010; 79(5-6):415-22. PubMed ID: 21474966
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer.
Larsen FO; Pfeiffer P; Nielsen D; Skougaard K; Qvortrup C; Vistisen K; Fromm AL; Jørgensen TL; Bjerregaard JK; Hoegdall E; Jensen BV
Acta Oncol; 2011 May; 50(4):574-7. PubMed ID: 21529301
[TBL] [Abstract][Full Text] [Related]
17. [A case of remnant liver metastases after resection of liver metastases from rectal cancer following treatment with 5-FU, L-OHP and CPT-11, with markedly effective treatment by cetuximab plus S-1].
Takeuchi M; Ogata Y; Ishibashi N; Uchida S; Murakami N; Kibe S; Takahashi K; Yahara T; Shirouzu K
Gan To Kagaku Ryoho; 2012 May; 39(5):843-6. PubMed ID: 22584346
[TBL] [Abstract][Full Text] [Related]
18. When more is worse in clinical research and clinical practice.
Tassinari D; Tombesi P; Sartori S
Am J Clin Oncol; 2010 Aug; 33(4):424. PubMed ID: 20689366
[No Abstract] [Full Text] [Related]
19. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
Soeda H; Shimodaira H; Gamoh M; Ando H; Isobe H; Suto T; Takahashi S; Kakudo Y; Amagai K; Mori T; Watanabe M; Yamaguchi T; Kato S; Ishioka C
Oncology; 2014; 87(1):7-20. PubMed ID: 24968756
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]